The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 370.00
Bid: 360.00
Ask: 380.00
Change: 0.00 (0.00%)
Spread: 20.00 (5.556%)
Open: 370.00
High: 370.00
Low: 370.00
Prev. Close: 370.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Mon, 11th Jan 2021 14:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Science Group PLC - Cambridge-based scientific consultancy services firm - Says it expects revenue for 2020 to soar 28% to GBP73 million from GBP57.2 million and for operating profit to beat its previously upgraded forecast of GBP10 million, up from GBP6.7 million in 2019. Says Finance Director Rebecca Archer will step down to take up a new role after completion of the 2020 results audit. Adds it has hired former Ted Baker interim finance director Sameet Vohra as chief financial officer designate.

----------

Rotala PLC - West Midlands-based bus operator - For financial 2020 ended November 30, expects to swing to pretax loss of GBP1.0 million from profit of GBP3.6 million the year before despite an increase in turnover to GBP76.0 million from GBP67.5 million. Blames the performance on Covid-19 lockdowns but notes the UK government grant package, the CBSSG Restart, helped its performance. However, it says the provisions of CBSSG Restart and the associated UK Government measures were designed to ensure it makes neither a profit nor a loss until the measures are terminated. As such, it expects to make neither a profit nor loss for financial 2021.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - Expects revenue for the six months ended December 31 to be around GBP4.1 million, down from GBP5.1 million the year prior, with UK sales declining due to a reduction in beauty category consumption amid the Covid-19 pandemic. Adds it has dismissed Joe Bayer from the role of chair effective immediately with existing Non-Executive Director Ross Andrews to replace him.

----------

W Resources PLC - London-based tungsten, tin and gold mining company with assets in Spain and Portugal - Draws down further GBP500,000 from its GBP4.0 million Atlas Capital Markets convertible bond facility, the second drawdown since the facility was secured in March 2020. This convertible bond tranche has a 5% coupon and 3-year term. The company will use the cash to advance the Regua mine development and provide additional working capital.

----------

AssetCo PLC - Middle East-focused provider of management and resources to the fire and emergency services - Says Aberdeen Asset Management Founder Martin Gilbert, Aberdeen's former global head of private markets Peter McKellar, various associates and funds managed by Toscafund Asset Management acquire a 29.8% stake at 475 pence per share. Following the receipt of regulatory approvals, Martin Gilbert and Peter McKellar will join the board as non-executive directors.

----------

MaxCyte Inc - Maryland-based cell and gene therapies firm - Inks a clinical and commercial licensing agreement with Myeloid Therapeutics to advance Myeloid's cell therapy programmes. Under the deal, Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte will receive development and approval milestones and sales-based payments, along with other licensing fees. No financial details were disclosed.

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - Enters strategic partnership with Inmagene Biopharmaceuticals to further develop four novel preclinical drug candidatesfor the potential treatment of multiple immunological diseases. The companies will work together to move the drug candidates towards investigational new drug submission. If successful, Inmagene will then move the drug candidates through global clinical development. For each of the drug candidates, Chi-Med will be entitled to development milestones of up to USD95 million and up to USD135 million in commercial milestones as well as up to double-digit royalties upon commercialization.

----------

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 May 2024 12:45

MaxCyte reports strong first quarter

(Sharecast News) - MaxCyte reported total first-quarter revenue of $11.3m in an update on Wednesday, making for a 32% increase compared to the same period in 2023.

Read more
8 May 2024 09:46

MaxCyte shares rise amid double-digit revenue increase

(Alliance News) - MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales.

Read more
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
30 Apr 2024 14:38

UK earnings, trading statements calendar - next 7 days

Wednesday 1 May 
Anexo Group PLCFull Year Results
Cambridge Cognition Holdings PLCFull Year Results
Computacenter PLCTrading Statement
Georgia Capital PLCQ1 Results
GSK PLCQ1 Results
Haleon PLCTrading Statement
HSS Hire Group PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Maintel Holdings PLCFull Year Results
Next PLCTrading Statement
Smith & Nephew PLCTrading Statement
Thursday 2 May 
Endeavour Mining PLCQ1 Results
First Tin PLCTrading Statement
Hiscox LtdTrading Statement
International Personal Finance PLCTrading Statement
Kerry Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
Melrose Industries PLCTrading Statement
NAHL Group PLCFull Year Results
Reach PLCTrading Statement
Shell PLCQ1 Results
Smiths News PLCHalf Year Results
Smurfit Kappa Group PLCTrading Statement
Spectris PLCTrading Statement
Standard Chartered PLCQ1 Results
TI Fluid Systems PLCQ1 Results
Friday 3 May 
InterContinental Hotels Group PLCTrading Statement
Mondi PLCTrading Statement
Trainline PLCFull Year Results
Monday 6 May 
no events scheduled 
Tuesday 7 May 
Arecor Therapeutics PLCFull Year Results
BP PLCQ1 Results
Ebiquity PLCFull Year Results
IWG PLCTrading Statement
Kosmos Energy LtdQ1 Results
MaxCyte IncQ1 Results
Trident Royalties PLCTrading Statement
Vaalco Energy IncQ1 Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
2 Apr 2024 15:19

TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Mar 2024 12:04

MaxCyte reports strong fourth quarter as full-year revenues fall

(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022.

Read more
13 Mar 2024 11:54

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples.

Read more
5 Mar 2024 20:43

EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Mar 2024 16:06

UK earnings, trading statements calendar - next 7 days

Wednesday 6 March 
Breedon Group PLCFull Year Results
Capita PLCFull Year Results
ConvaTec Group PLCFull Year Results
DS Smith PLCTrading Statement
Galliford Try Holdings PLCHalf Year Results
Greencoat Renewables PLCFull Year Results
Ibstock PLCFull Year Results
Lancashire Holdings LtdFull Year Results
Legal & General Group PLCFull Year Results
Netcall PLCHalf Year Results
Nexxen International LtdFull Year Results
Nichols PLCFull Year Results
Quilter PLCFull Year Results
Rathbones Group PLCFull Year Results
Ricardo PLCFull Year Results
Spirent Communications PLCFull Year Results
TClarke PLCFull Year Results
Tullow Oil PLCFull Year Results
CLS Holdings PLCFull Year Results
Thursday 7 March 
Admiral Group PLCFull Year Results
Aviva PLCFull Year Results
Beazley PLCFull Year Results
Brooks Macdonald Group PLCHalf Year Results
Coats Group PLCFull Year Results
Darktrace PLCHalf Year Results
Elementis PLCFull Year Results
Entain PLCFull Year Results
Funding Circle Holdings PLCFull Year Results
Harbour Energy PLCFull Year Results
ITV PLCFull Year Results
Kier Group PLCFull Year Results
Melrose Industries PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
PageGroup PLCFull Year Results
Physiomics PLCHalf Year Results
Rentokil Initial PLCFull Year Results
Robert Walters PLCFull Year Results
Spirax-Sarco Engineering PLCFull Year Results
TT Electronics PLCFull Year Results
Tyman PLCFull Year Results
Friday 8 March 
Informa PLCFull Year Results
Just Group PLCFull Year Results
LMS Capital PLCFull Year Results
Stelrad Group PLCFull Year Results
Monday 11 March 
HgCapital Trust PLCFull Year Results
Mincon Group PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Tuesday 12 March 
BATM Advanced Communications LtdFull Year Results
Costain Group PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
Foresight Solar Fund LtdFull Year Results
Genuit PLCFull Year Results
H&T Group PLCFull Year Results
Hill & Smith PLCFull Year Results
MaxCyte IncFull Year Results
Persimmon PLCFull Year Results
Synthomer PLCFull Year Results
Target Healthcare REIT PLCHalf Year Results
TI Fluid Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
5 Mar 2024 13:01

MaxCyte flags lower 2023 revenue, flat 2024 growth

(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022.

Read more
30 Jan 2024 13:58

IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided.

Read more
29 Jan 2024 17:56

IN BRIEF: MaxCyte chief scientific officer leaves firm

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board.

Read more
23 Jan 2024 18:39

TRADING UPDATES: Esken's Southend Airport faces further allegations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Jan 2024 12:18

MaxCyte's strategic platform licences redeem otherwise modest results

(Alliance News) - MaxCyte Inc on Tuesday said that promising returns from its strategic platform licence program had bolstered its quarterly revenue expectations.

Read more
9 Jan 2024 08:55

MaxCyte flags uptick in total fourth-quarter revenue

(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.